Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery

Pharmacogenomics

Volumn 15, Issue 16, 2014, Pages 1943-1946

  Schubert, Michael ^a   Iorio, Francesco ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

cancer genomics; co occurrent mutations; data mining; data driven analyses; mutual exclusivity; synthetic lethality

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE; SCATTER FACTOR RECEPTOR;

CANCER CELL LINE; CANCER GENETICS; CANCER RESEARCH; CELL SUBPOPULATION; ENZYME INHIBITION; EVOLUTIONARY ADAPTATION; GENE SEQUENCE; GENE SILENCING; GENOTYPE; HUMAN; MUTATIONAL ANALYSIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR GENE;

EID: 84919787552     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.157     Document Type: Review

References (20)

1. International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects. Nature 464(7291), 993-998 (2010
2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008
3. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391), 570-575 (2012
4. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603-607 (2012
5. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415-421 (2013
6. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nature Genet. 45(10), 1127-1133 (2013
7. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011
9. McDermott U, Sharma S, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-Throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104(50), 19936-19941 (2007
10. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 463(7283), 893-898 (2010
11. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22(2), 398-406 (2012
12. Vandin F, Upfal E, Raphael BJ. De novo discovery of mutated driver pathways in cancer. Genome Res. 22(2), 375-385 (2012
13. Uren AG, Kool J, Matentzoglu K, et al. Large-Scale Mutagenesis in p19ARF-And p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks. Cell 133(4), 727-741 (2008
14. Nijman SMB. Synthetic lethality: General principles, utility and detection using genetic screens in human cells. FEBS Lett. 585(1), 1-6 (2011
15. Cheung HW, Cowley GS, Weir BA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. USA 108(30), 12372-12377 (2011
16. Bommi-Reddy A, Almeciga I, Sawyer J, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/-cancer cells detected in a pilot synthetic lethal screen. Proc. Natl Acad. Sci. USA 105(43), 16484-16489 (2008
17. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005
18. Jerby-Arnon L, Pfetzer N, Waldman YY, et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 158(5), 1199-1209 (2014
19. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011
20. Gobbi A, Iorio F, Dawson KJ, et al. Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics 30(17), i617-i623 (2014